- Investing.com
Jiangsu Hengrui Medicine Co., Ltd., a pharmaceutical company, develops, manufactures, and commercializes drugs worldwide. The company is developing Camrelizumab, Pyrotinib, Fuzuloparib, Adebrelimab, Rezvilutamide, Famitinib, Dalpiciclib, SHR-1701, SHR-1501, SHR-A1811, SHR1459, Mecapegfilgrastim, Apatinib, Linperlisib, and SHR2554 for oncology indications; SHR4640, Retagliptin, SHR20004, SHR-1209, SHR3824, INS068, SHR7280, and SHR2285 for cardiovascular and metabolism indications. It is also developing SHR0302, Hetrombopag, Vunakizumab, and SHR-1703 for autoimmune indications; SHR0410, Imrecoxib, Remimazolam, and SHR8554 for pain; Oteseconazole and HRS9950 for anti-infection; and SHR8028, SHR8058, SHR-1707, and SHR-1222 for other indications. The company was founded in 1970 and is based in Lianyungang, China.
Metrics to compare | 600276 | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship Relationship600276PeersSector | |
---|---|---|---|---|
P/E Ratio | 57.8x | 18.1x | −0.6x | |
PEG Ratio | 1.88 | −0.52 | 0.00 | |
Price/Book | 7.2x | 2.2x | 2.6x | |
Price / LTM Sales | 12.1x | 2.4x | 3.2x | |
Upside (Analyst Target) | 16.0% | 15.5% | 43.4% | |
Fair Value Upside | Unlock | 19.2% | 6.4% | Unlock |